Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells

Oncogene

Volumn 32, Issue 5, 2013, Pages 651-662

  Calhabeu, F ^a   Hayashi, S ^b   Morgan, J E ^c   Relaix, F ^b   Zammit, P S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSERM   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

alveolar rhabdomyosarcoma; MyoD; myogenin; PAX3 FOXO1A; PAX7 FOXO1A; satellite cell

Indexed keywords

CREATINE KINASE MM; HISTONE H4; MYOD PROTEIN; MYOGENIN; RNA POLYMERASE II; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; MOUSE; MUSCLE; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RHABDOMYOSARCOMA; SATELLITE CELL; STEM CELL;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CREATINE KINASE, MM FORM; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; MICE; MYOD PROTEIN; MYOGENIN; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; RHABDOMYOSARCOMA, ALVEOLAR; SATELLITE CELLS, SKELETAL MUSCLE; STEM CELLS;

MURINAE; MUS;

EID: 84873406189     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.73     Document Type: Article

References (58)

1. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001; 20: 5736 - 5746. (Pubitemid 32928111)
2. Miller PJ, Hollenbach AD. The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. Biochim Biophys Acta 2007; 1770: 1450 - 1458. (Pubitemid 47384992)
3. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995; 15: 1522 - 1535.
4. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66: 6936 - 6946. (Pubitemid 44197668)
5. Begum S, Emami N, Cheung A, Wilkins O, Der S, Hamel PA. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 2005; 24: 1860 - 1872. (Pubitemid 40462788)
6. Bennicelli JL, Advani S, Schafer BW, Barr FG. PAX3 and PAX7 exhibit conserved cisacting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 1999; 18: 4348 - 4356. (Pubitemid 29392375)
7. Epstein JA, Song B, Lakkis M, Wang C. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 1998; 18: 4118 - 4130. (Pubitemid 28287935)
8. Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol 2007; 23: 645 - 673.
9. Relaix F, Rocancourt D, Mansouri A, Buckingham M. A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. Nature 2005; 435: 948 - 953. (Pubitemid 40896320)
10. Lepper C, Conway SJ, Fan CM. Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements. Nature 2009; 460: 627 - 631.
11. Relaix F, Montarras D, Zaffran S, Gayraud-Morel B, Rocancourt D, Tajbakhsh S et al. Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J Cell Biol 2006; 172: 91 - 102. (Pubitemid 43042632)
12. Zammit PS, Relaix F, Nagata Y, Ruiz AP, Collins CA, Partridge TA et al. Pax7 and myogenic progression in skeletal muscle satellite cells. J Cell Sci 2006; 119(Pt 9): 1824 - 1832. (Pubitemid 43811008)
13. Zammit PS, Golding JP, Nagata Y, Hudon V, Partridge TA, Beauchamp Jr. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? J Cell Biol 2004; 166: 347 - 357. (Pubitemid 39031238)
14. Relaix F, Polimeni M, Rocancourt D, Ponzetto C, Schafer BW, Buckingham M. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev 2003; 17: 2950 - 2965. (Pubitemid 37523158)
15. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010; 70: 6497 - 6508.
16. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993; 259: 1450 - 1453. (Pubitemid 23101380)
17. Weintraub M, Kalebic T, Helman LJ, Bhatia KG. Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma. Sarcoma 1997; 1: 135 - 141. (Pubitemid 28267181)
18. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342 - 352.
19. Gurney JG, Young JL, Roffers SD, Smith MA, Bunin GR. Soft Tissue Sarcomas. In: Ries LAG SM, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975 - 1995. National Cancer Institute: Bethesda, MD, 1999, pp 111 - 123.
20. Cui S, Hano H, Harada T, Takai S, Masui F, Ushigome S. Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma. Pathol Int 1999; 49: 62 - 68. (Pubitemid 29421949)
21. Maroto M, Reshef R, Munsterberg AE, Koester S, Goulding M, Lassar AB. Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 1997; 89: 139 - 148. (Pubitemid 27180593)
22. Keller C, Hansen MS, Coffin CM, Capecchi MR. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 2004; 18: 2608 - 2613. (Pubitemid 39453100)
23. Nishijo K, Hosoyama T, Bjornson CR, Schaffer BS, Prajapati SI, Bahadur AN et al. Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J 2009; 23: 2681 - 2690.
24. Hettmer S, Wagers AJ. Muscling in: uncovering the origins of rhabdomyosarcoma. Nat Med 2010; 16: 171 - 173.
25. Gnocchi VF, White RB, Ono Y, Ellis JA, Zammit PS. Further characterisation of the molecular signature of quiescent and activated mouse muscle satellite cells. PLoS ONE 2009; 4: e5205.
26. Epstein JA, Lam P, Jepeal L, Maas RL, Shapiro DN. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 1995; 270: 11719 - 11722.
27. Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, Adam MA, Lassar AB et al. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci USA 1989; 86: 5434 - 5438. (Pubitemid 19185563)
28. Russo S, Tomatis D, Collo G, Tarone G, Tato F. Myogenic conversion of NIH3T3 cells by exogenous MyoD family members: dissociation of terminal differentiation from myotube formation. J Cell Sci 1998; 111 (Pt 6): 691 - 700. (Pubitemid 28163878)
29. Graf Finckenstein F, Shahbazian V, Davicioni E, Ren YX, Anderson MJ. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene 2008; 27: 2004 - 2014. (Pubitemid 351442734)
30. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3- FKHR fusion oncogene. Proc Natl Acad Sci USA 1999; 96: 13264 - 13269.
31. Scuoppo C, Riess I, Schmitt-Ney M, Allegra P, Forni PE, Bersani F et al. The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes. Exp Cell Res 2007; 313: 2308 - 2317. (Pubitemid 46891463)
32. Berkes CA, Tapscott SJ. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 2005; 16: 585 - 595. (Pubitemid 41247882)
33. Montarras D, Morgan J, Collins C, Relaix F, Zaffran S, Cumano A et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005; 309: 2064 - 2067. (Pubitemid 41362326)
34. Wei Q, Paterson BM. Regulation of MyoD function in the dividing myoblast. FEBS Lett 2001; 490: 171 - 178. (Pubitemid 32171936)
35. Tapscott SJ. The circuitry of a master switch: Myod and the regulation of skeletal muscle gene transcription. Development 2005; 132: 2685 - 2695. (Pubitemid 40932860)
36. Collins CA, Gnocchi VF, White RB, Boldrin L, Perez-Ruiz A, Relaix F et al. Integrated functions of Pax3 and Pax7 in the regulation of proliferation, cell size and myogenic differentiation. PLoS ONE 2009; 4: e4475.
37. Relaix F, Rocancourt D, Mansouri A, Buckingham M. Divergent functions of murine Pax3 and Pax7 in limb muscle development. Genes Dev 2004; 18: 1088 - 1105. (Pubitemid 38620247)
38. Tajbakhsh S, Rocancourt D, Cossu G, Buckingham M. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 1997; 89: 127 - 138. (Pubitemid 27180592)
39. Dilworth FJ, Seaver KJ, Fishburn AL, Htet SL, Tapscott SJ. In vitro transcription system delineates the distinct roles of the coactivators pCAF and p300 during MyoD/E47-dependent transactivation. Proc Natl Acad Sci USA 2004; 101: 11593 - 11598. (Pubitemid 39095341)
40. Guo K, Wang J, Andres V, Smith RC, Walsh K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 1995; 15: 3823 - 3829.
41. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018 - 1021.
42. Otten AD, Firpo EJ, Gerber AN, Brody LL, Roberts JM, Tapscott SJ. Inactivation of MyoD-mediated expression of p21 in tumor cell lines. Cell Growth Differ 1997; 8: 1151 - 1160. (Pubitemid 27481651)
43. Song A, Wang Q, Goebl MG, Harrington MA. Phosphorylation of nuclear MyoD is required for its rapid degradation. Mol Cell Biol 1998; 18: 4994 - 4999. (Pubitemid 28388082)
44. Zhang L, Wang C. Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. Oncogene 2007; 26: 1595 - 1605. (Pubitemid 46398742)
45. Bajard L, Relaix F, Lagha M, Rocancourt D, Daubas P, Buckingham ME. A novel genetic hierarchy functions during hypaxial myogenesis: Pax3 directly activates Myf5 in muscle progenitor cells in the limb. Genes Dev 2006; 20: 2450 - 2464. (Pubitemid 44320392)
46. Lagha M, Kormish JD, Rocancourt D, Manceau M, Epstein JA, Zaret KS et al. Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program. Genes Dev 2008; 22: 1828 - 1837. (Pubitemid 351915507)
47. Ono Y, Boldrin L, Knopp P, Morgan JE, Zammit PS. Muscle satellite cells are a functionally heterogeneous population in both somite-derived and branchiomeric muscles. Dev Biol 2010; 337: 29 - 41.
48. Horst D, Ustanina S, Sergi C, Mikuz G, Juergens H, Braun T et al. Comparative expression analysis of Pax3 and Pax7 during mouse myogenesis. Int J Dev Biol 2006; 50: 47-54. (Pubitemid 43145109)
49. Kelly KM, Womer RB, Sorensen PH, Xiong QB, Barr FG. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997; 15: 1831 - 1836. (Pubitemid 27209511)
50. del Peso L, Gonzalez VM, Hernandez R, Barr FG, Nunez G. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 1999; 18: 7328 - 7333. (Pubitemid 30032113)
51. L'Honore A, Rana V, Arsic N, Franckhauser C, Lamb NJ, Fernandez A. Identification of a new hybrid serum response factor and myocyte enhancer factor 2-binding element in MyoD enhancer required for MyoD expression during myogenesis. Mol Biol Cell 2007; 18: 1992 - 2001. (Pubitemid 46911352)
52. Ornatsky OI, Andreucci JJ, McDermott JC. A dominant-negative form of transcription factor MEF2 inhibits myogenesis. J Biol Chem 1997; 272: 33271 - 33278. (Pubitemid 28023675)
53. Yang Z, MacQuarrie KL, Analau E, Tyler AE, Dilworth FJ, Cao Y et al. MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev 2009; 23: 694 - 707.
54. Saccone V, Puri PL. Epigenetic regulation of skeletal myogenesis. Organogenesis 2010; 6: 48-53.
55. Sartorelli V, Puri PL, Hamamori Y, Ogryzko V, Chung G, Nakatani Y et al. Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program. Mol Cell 1999; 4: 725 - 734.
56. Nakajima T, Uchida C, Anderson SF, Lee CG, Hurwitz J, Parvin JD et al. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 1997; 90: 1107 - 1112. (Pubitemid 27408524)
57. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910 - 2919.
58. Spitz F, Demignon J, Porteu A, Kahn A, Concordet JP, Daegelen D et al. Expression of myogenin during embryogenesis is controlled by Six/sine oculis homeoproteins through a conserved MEF3 binding site. Proc Natl Acad Sci USA 1998; 95: 14220 - 14225. (Pubitemid 28549348)